CARCML = Efficacy and Safety of Generic Imatinib Compared to Glivec® in Real-Life Management of Chronic Phase of Chronic Myeloid Leukemia [Egypt]

This study includes patients of all sexes who:

• are aged 18 years and older.
• have been newly diagnosed with Philadelphia chromosome positive (Ph+) CML in chronic phase, with or without the presence of other cytogenetic abnormalities at the time of diagnosis.
• have not received treatment for CML within 3 months of study enrolment.

Further criteria may apply. Please discuss these with your doctor or study staff.

This study does not include patients who:

• have CML in accelerated phase (AP) at the time of enrolment except patients in AP who present other cytogenetic abnormalities at the time of diagnosis.
• have CML in blast phase at the time of enrolment.
• meet any of the contraindications to the administration of the study drug according to the approved Summary of Product Characteristics.